Sunesis completes safety evaluation period for cohort in Phase 1b/2 trial
Sunesis Pharmaceuticals announced the promotion of Judy Fox, Ph.D. from CSO, SVP to CSO, EVP, Research & Development and the promotion of Parvinder Hyare from VP, Global Oncology Operations to SVP, Commercial. Fox rejoined Sunesis in 2017 as Chief Scientific Officer and program leader for vecabrutinib. Hyare joined Sunesis in July 2014. The company also announced that it has completed the safety evaluation period for the 200 mg cohort of the ongoing Phase 1b/2 trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia and other B-cell malignancies. To date, vecabrutinib has a favorable safety profile with no drug-related serious adverse events, supporting dose escalation to Cohort 5. This cohort is now open.